Nivolumab-based treatment (N+AVD) improves progression-free survival in advanced-stage Hodgkin’s lymphoma patients compared ...

Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a combination therapy consisting of ...

Arbutus Biopharma Corporation and Barinthus Biotherapeutics recently unveiled encouraging preliminary results from their ...

A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a ...

Patients with dMMR colon cancer in a trial for two neoadjuvant cycles of nivolumab/ipilimumab or nivolumab/relatlimab, had ...

The combination of vidutolimod and nivolumab “stimulates a broad antitumor immune response,” according to researchers.

Arbutus Biopharma (ABUS) and Barinthus Biotherapeutics (BRNS) announced new preliminary data from the Phase 2a IM-PROVE II clinical trial of ...

The N-AVD regimen showed improved progression-free survival and lower toxicity than BV-AVD in advanced Hodgkin lymphoma, ...

Eight participants achieved HBsAg loss at any time.Two participants met criteria for functional cure. Two participants who discontinued NUC ...

(Alliance News) - Scancell Holdings PLC on Monday reported positive data from an ongoing trial on patients receiving a treatment combination for advanced melanoma, a skin cancer.

The study added to a limited database about the effects of perioperative IO combinations, which have emerged as standard of ...

During a Case-Based Roundtable® event, Patrick M. Forde, MD, discussed safety and tolerability concerns with immunotherapy in ...